CJC-1295 with drug affinity complex is a long-acting GHRH analog. Learn how the DAC extends half-life, how it compares to Mod GRF, and safety facts.
CJC-1295 with drug affinity complex — usually shortened to CJC-1295 DAC — is a synthetic growth hormone-releasing hormone (GHRH) analog with a chemical linker called a drug affinity complex attached to one end. That linker binds to albumin in the bloodstream, which shields the peptide from rapid enzyme breakdown and stretches its half-life from minutes to roughly a week in animal and laboratory research. CJC-1295 is a research chemical only: it is not FDA-approved for human use, and it is not a legal dietary supplement in the United States.
CJC-1295 sits in the same family as modified GRF (1-29), also called Mod GRF or sermorelin-related peptides. The difference is the DAC tail, and that single addition changes almost everything about how the peptide behaves in a research setting.
What the Drug Affinity Complex Actually Does
The drug affinity complex is a maleimidopropionic acid group that reacts with the cysteine-34 residue on human serum albumin. Once bound, the peptide travels through the body attached to albumin rather than being cleared within minutes by DPP-4 and other peptidases.
Three practical effects follow from that binding:
- Longer circulation time. Research models show a half-life of roughly 5 to 8 days for CJC-1295 DAC, compared with about 30 minutes for unmodified GHRH.
- Slower clearance. Albumin acts as a reservoir that releases the peptide gradually instead of all at once.
- Different exposure profile. Instead of a short spike, researchers observe a sustained elevation in measurable GH and IGF-1 markers in animal studies.
The DAC does not make the peptide more potent at the receptor. It changes pharmacokinetics, not receptor affinity.
CJC-1295 With DAC vs. CJC-1295 Without It
Researchers comparing the two forms usually ask the same question: does the albumin-binding tail change results enough to matter? In most published animal work, it changes duration far more than peak effect. The table below summarizes how the DAC version differs from cjc-1295 without drug affinity complex.
| Feature | CJC-1295 with DAC | CJC-1295 without DAC (Mod GRF 1-29) |
|---|---|---|
| Half-life in research models | About 5–8 days | About 30 minutes |
| Albumin binding | Yes, covalent | No |
| Research dosing interval | Every few days to weekly | One to three times daily |
| Molecular additions | MPA linker plus four substitutions | Four substitutions only |
| GH and IGF-1 pattern | Sustained elevation | Short pulse |
The most consistent finding across animal studies is that CJC-1295 DAC produces a prolonged rise in IGF-1, while the non-DAC form produces sharper, shorter spikes. Whether that pattern is preferable remains an open research question.
Half-Life and Dosing Questions
Search interest in cjc-1295 with dac dosage is high, but no FDA-approved dosing schedule exists for this compound because it has never been approved for human use. Published animal studies used single doses in the range of roughly 1–2 mg per kilogram, and that number does not translate directly into human guidance.
People who ask how much cjc 1295 with dac should i take are usually reading forum posts rather than clinical literature. Any figure circulating on forums is anecdotal, unverified, and not a substitute for advice from a licensed healthcare professional.
Two points are worth stating plainly:
- No regulatory agency has established a safe or effective human dose of CJC-1295 DAC.
- Because the half-life is measured in days, a poorly chosen amount cannot be quickly cleared from the body.
Forms, Vials, and Sourcing
CJC-1295 DAC is sold almost exclusively as a lyophilized powder in sealed vials, most often labeled "for research use only." Common vial sizes are 2 mg, 5 mg, and 10 mg, and purity claims above 98% are typical.
Sourcing is where the risk concentrates. Peptides marketed for human consumption without a prescription sit in a legal gray zone in the US, and independent testing has repeatedly found mislabeled or underdosed products in this category. A certificate of analysis from the seller is a starting point, not proof.
Selling a research peptide does not make it legal to use in humans, and "research use only" labeling is not a legal shield for consumers.
Combination Research and Stacking
In laboratory and self-experimentation settings, CJC-1295 DAC is frequently paired with a ghrelin-receptor agonist such as ipamorelin. The rationale is that GHRH and ghrelin pathways act on the pituitary through different receptors, so stimulating both may produce a larger GH signal than either alone. Anyone researching cjc 1295 with ipamorelin peptide should note that the two compounds have very different half-lives, which complicates any comparison to single-peptide studies.
Newer combinations, including GLP-1 receptor agonists, are discussed online but have essentially no published data on co-administration with GHRH analogs. Combining unapproved peptides amplifies unknown risks rather than reducing them.
Safety, Legal Status, and Online Claims
CJC-1295 has not been evaluated in large human trials, so its long-term safety profile is unknown. Effects described in informal accounts include injection-site reactions, flushing, headache, and changes in appetite or sleep.
Because growth hormone and IGF-1 influence many tissues, sustained elevation of these hormones is not automatically harmless. Excess GH signaling has been associated with joint pain, fluid retention, insulin resistance, and in chronic cases, organ enlargement. Anyone with a hormone-sensitive condition, active cancer, or diabetes should treat these compounds as off-limits without medical supervision.
Legal status varies by country. In the US, CJC-1295 is not an approved drug and is not a lawful dietary supplement ingredient, and importing it for personal use is not authorized. Regulators have issued warnings about peptides marketed as research chemicals when the vendor's real customer base is consumers.
Community posts — the kind of discussion people find when they search cjc 1295 with dac reddit — tend to mix genuine personal reports with vendor promotion. Anecdotes are not evidence, and the loudest voices in peptide forums often have a commercial stake in the answer.
Bottom Line
The drug affinity complex is a delivery modification, not a new mechanism. It makes CJC-1295 last for days instead of minutes by attaching the peptide to albumin, which is why the DAC version is studied at far longer intervals than Mod GRF 1-29.
CJC-1295 with drug affinity complex remains an unapproved research chemical. Talk with a licensed healthcare professional before considering any peptide that is not prescribed, and treat forum dosing advice as unverified opinion.
Frequently Asked Questions
What does the drug affinity complex do in CJC-1295?
The drug affinity complex is a maleimidopropionic acid linker that binds covalently to albumin in the blood. That binding slows enzymatic breakdown and extends the peptide's half-life from roughly 30 minutes to about 5–8 days in research models. It changes how long the peptide circulates, not how strongly it binds its receptor.
Is CJC-1295 with DAC FDA-approved or legal to buy in the US?
No. CJC-1295 has never been approved by the FDA for human use, and it is not a lawful dietary supplement ingredient in the United States. Products labeled "for research use only" are sold in a legal gray zone, and importing the peptide for personal use is not authorized.
How is CJC-1295 with DAC different from CJC-1295 without DAC?
CJC-1295 without the drug affinity complex — often called Mod GRF 1-29 — lacks the albumin-binding linker and clears the body within about 30 minutes. The DAC version stays active for days, so research protocols use much longer intervals between exposures. Animal data suggest the DAC form produces a sustained IGF-1 rise, while the non-DAC form produces brief pulses.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.